- Mesoblast (MSB) sees its drug, rexlemestrocel-L, improve the main chamber of the heart, the left ventricle, in a trial in New York
- The company tested the drug on patients with systolic heart failure or heart failure with reduced ejection fraction
- From the trial, improvement was shown in the pre-specified analysis of left ventricular ejection fraction (LVEF) at 12 months
- The trial reported a 68 per cent drop in the rate of recurrent hospitalisations from non-fatal heart attacks or strokes compared with controls
- Mesoblast intends to meet with the US FDA to discuss its trial and how the outcomes may support regulatory approval for rexlemestrocel-L
- MSB ends the day 7.60 per cent in the green to close at 92 cents
Mesoblast (MSB) has seen its drug, rexlemestrocel-L, improve the main chamber of the heart, the left ventricle, in a trial in New York.
The company tested the drug on patients with systolic heart failure or heart failure with reduced ejection fraction (HFrEF).
From the trial, improvement was shown in the pre-specified analysis of left ventricular ejection fraction (LVEF) at 12 months, preceding long-term reduction in major adverse cardiovascular events.
Results show that the improvement in LVEF was most noticeable in inflammation and a long-term reduction in major adverse cardiovascular events and associated recurrent hospitalisations for a non-fatal heart attack or stroke.
The trial reported a 68 per cent drop in the rate of recurrent hospitalisations from non-fatal heart attacks or strokes compared with controls.
According to the company, heart failure affects around 6.5 million people in the US and 26 million around the globe, with increasing prevalence and incidence.
“Despite recent approvals of new therapies for HFrEF, including SGLT2 inhibitors, that have reduced hospitalisations due to reversible volume-related events, NYHA class
II/III HFrEF patients with inflammation remain at high risk for cardiac death, heart attacks and strokes,” the company said.
“Over 60,000 patients annually in the US progress to end-stage heart failure (NYHA class IV) and these patients have a one-year mortality exceeding 50 per cent.”
Mesoblast now intends to meet with the US FDA to discuss its trial and how the outcomes may support regulatory approval for rexlemestroc-L.
MSB ended the dat 7.60 per cent in the green to close at 92 cents.